Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

As the Use of AI In Healthcare Grows, Cardio Diagnostic Is Using It In Quest to Help Prevent Cardiovascular Disease

Cardio Diagnostics Holdings, Inc

By Faith Ashmore, Benzinga In the United States, one person dies from cardiovascular disease every 33 seconds, and nearly one in every four deaths is attributed to heart disease. It is the leading cause of death for men, women and people of most racial and ethnic groups across the board. In 2021, cardiovascular disease cost the U.S. approximately $219 billion and those numbers are only expected to go up if nothing changes. Fortunately, many of the deaths associated with heart disease are preventable if health professionals are able to leverage modern technology to educate and treat effectively. The Global Burden of Disease (GBD) study and the Global Burden of Cardiovascular Diseases Collaboration have provided valuable perspectives on the urgency of developing comprehensive strategies to address these risks and enhance public health. According to Gregory A. Roth, MD, MPH, the senior author of the paper, associate professor in the Division of Cardiology, and director of the Program in Cardiovascular Health Metrics at the Institute for Health Metrics and Evaluation at the University of Washington, "Cardiovascular diseases continue to pose a persistent challenge, resulting in a significant number of premature and preventable deaths." Combining advanced clinical diagnostic solutions with digital health, Artificial Intelligence (AI) and value-based care initiatives can accelerate how organizations tackle cardiovascular disease. How AI Can Be Instrumental In The Fight Against Heart Disease In 2023, the market for AI in healthcare was forecasted to reach $20.65 billion, and it is predicted to reach $187.95 billion by 2030. This is not surprising to most because the implementation of AI in healthcare has brought about a transformative shift in the industry, enabling a personalized approach to patient care. AI algorithms can effectively handle and analyze extensive medical data, including epigenetic, genetic information and DNA-based biomarkers. Healthcare providers now have the capability to make precise and personalized treatment choices, taking into account an individual's specific biology, which ultimately enhances patient outcomes. By utilizing AI-powered systems, patterns can be identified, potential health issues can be predicted, and real-time monitoring can be conducted, facilitating early intervention and preventive measures. Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, is one company leading the charge in developing solutions to combat cardiovascular disease. Both the mission and capabilities of Cardio Diagnostics align with the healthcare sector's demands for leveraging cutting-edge molecular and AI technologies to drive preventive care, earlier disease detection, and chronic disease management. By employing AI and machine learning, the company can help empower healthcare providers to proactively identify high-risk populations and intervene early, leading to enhanced health outcomes and cost reductions across a broad spectrum of organizations. How The Use of Telemedicine Is Making Care More Accessible To All Communities COVID-19 dramatically changed the landscape of telehealth, and four years after the pandemic began, it looks like telehealth is here to stay. In 2023, MGMA Stat did a poll with medical group leaders to get an understanding of the current landscape of telehealth – 45% believed telehealth demand would remain mostly the same, while 27% of respondents said they expected an increase. Telemedicine capabilities have been especially helpful in rural areas that had been experiencing physician shortages before the pandemic. In rural communities, Cardio Diagnostics makes specialty cardiovascular care accessible. The divide between urban and rural healthcare options can be bridged by deploying innovative solutions. When provider organizations and employers in rural settings adopt Cardio’s solutions, which couple telehealth to advanced AI-powered DNA tests, they can drive access to highly accurate diagnostics without extensive travel or the need for specialized infrastructure. The company's solutions enhance accessibility and convenience while optimizing specialty care for patients in underserved communities where travel distances and limited access to healthcare facilities present roadblocks to timely medical attention. Cardio Diagnostics empowers healthcare organizations by enabling primary care physicians to identify cardiovascular risk and status upstream before specialty cardiology becomes necessary, ultimately delivering value-based care. The Future Of Healthcare As cardiovascular disease remains a major concern for doctors and families, modern technology must evolve how we approach prevention and treatment. Companies like Cardio Diagnostics are key to bringing AI into the fold while using digital health technologies such as telemedicine to expand healthcare possibilities and provide value-based care. Featured photo by National Cancer Institute on Unsplash. Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com. Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," “goal,” or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, regulatory matters, protection of technology, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-K for the period ended December 31, 2022 and Form 10-Q for the period ended March 31, 2023, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Gene Mannheimer - Investor Relations +1 855-226-9991 investors@cardiodiagnosticsinc.com Company Website https://cardiodiagnosticsinc.com/

April 24, 2024 08:30 AM Eastern Daylight Time

Image

90% Of Americans Believe We Are Experiencing A Mental Health Care Crisis – Elevate Health And Wellness Is Providing Relief

Benzinga

By Faith Ashmore, Benzinga While the mental health crisis has been slowly brewing for decades, the global pandemic truly shined a spotlight on how many millions of Americans are struggling with mental health. Since the onset of the pandemic, 38% more Americans are participating in mental health care treatment of some kind, whether that be inpatient or outpatient services. Meanwhile, a recent poll done by CNN and the Kaiser Family Foundation showed that an overwhelming majority of Americans, roughly 90%, believe we are currently experiencing a mental health care crisis. The mental healthcare space is experiencing spikes in multiple different areas. One of the more concerning areas that are alarming professionals and the public alike is how youth mental health continues to worsen. In 2021, more than 4 in 10 students felt persistently sad or hopeless, with more than 1 in 5 students seriously considering attempting suicide. Serious mental health diagnoses and rates of addiction have also seen an uptick in recent years. In 2022, the CDC reported 105,454 drug overdose deaths, which was more than double the number from 2015 and a fivefold increase from 2002. Many of these overdoses were among middle-aged men, where an epidemic of loneliness has been reported. Now, more than ever, there is a need for high-quality mental healthcare facilities that can be a beacon of hope for millions of Americans. How Elevate Health And Wellness Is Revolutionizing The Health Care Industry Elevate Health and Wellness is a dual-licensed outpatient clinic that specializes in mental health and addiction treatment for adolescents and adults in Westport, CT; it provides unique in-person visits and electronic communication software in-between visits. The company’s mission is to provide accessible, compassionate and comprehensive treatment services, and, differentiating it from many competitors, the company has made accepting insurance a key part of its platform. The lack of insurance accepted at inpatient services has historically been a barrier to entry for people who need help and are in a vulnerable position. The clinic offers a range of in-network services that include outpatient detoxification, medication evaluation and management, individual and family psychotherapy, ADHD evaluation and testing, therapy services, and intensive outpatient programs for adolescents and adults. While many inpatient services do not have a full ecosystem that includes outpatient services, Elevate prides itself on its comprehensive approach to mental health care. The company services over 3,000 patients through its outpatient services and has virtual software to help connect patients to treatment providers with ease. Elevate's cohesive interdisciplinary team of psychiatrists, clinical psychologists, and licensed psychotherapists ensures that every patient receives quality care. The company looks at mental healthcare from a holistic approach and provides nutrition and fitness programs as well as primary care opportunities to ensure that patients have the tools necessary to live healthy and happy lives. Elevate is also in the process of obtaining a Certificate of Need (CON) for a new location in Clinton, Connecticut. This expansion aims to meet the growing need for inpatient residential facilities for adult and adolescent populations struggling with mental illness or co-morbid disorders. As Americans grapple with the ongoing mental health care crisis, companies like Elevate are champions for those who are struggling. Featured photo by Anthony Tran on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

April 24, 2024 08:25 AM Eastern Daylight Time

Image

AGC Biologics Announces Successful Completion of Production of Cancer-Specific Therapeutic Antibody Fragments with Var2 Pharmaceuticals

AGC Biologics

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced the completion of work with VAR2 Pharmaceuticals on the production of the company’s two antibody candidates targeting cancer-specific carbohydrate structures for cancer treatment. The CDMO’s work included information transfer and master cell bank creation, method implementation, pilot-scale evaluations, preparation for large-scale manufacturing, regulatory documentation support for EMA or FDA guidelines and product stability studies. "We prioritize unparalleled support for every project we undertake, ensuring our clients receive the highest level of service and satisfaction. This project is a good example of how fast we are able to deliver results in close collaboration with our clients," said Dieter Kramer, General Manager of AGC Biologics Heidelberg. VAR2 Pharmaceuticals proprietary antibody fragments –Vartumabs – have been shown to bind with high affinity and high specificity to onco-fetal Chondroitin Sulfate, a pan-cancer, tumor-specific glycosaminoglycan first identified by VAR2 Pharmaceuticals. The two antibody fragments produced in collaboration with AGC Biologics will be used in an upcoming, first-in-human, nuclear imaging microdosing study paving the way for efficacy trials with an ADC. AGC Biologics runs multiple cGMP microbial production lines at its Heidelberg facility. The AGC Biologics Heidelberg site has produced biologics products for 40 years and has built a track record for navigating clients through the early clinical phases and into later stages, including commercial production. In addition to protein-based biologics, the site serves as the CDMO’s Center of Excellence for plasmid DNA (pDNA) and messenger RNA (mRNA), offering full-scale support for microbial drug substances, plasmid materials, starting material for in-vitro transcription mRNA vaccines, and raw material for adeno-associated vectors and lentiviral vectors. The AGC Biologics Heidelberg facility has been producing biopharmaceuticals for four decades. The facility offers developer partners a segregated line design that increases flexibility and cGMP compliance. To learn more about microbial system-based biologics, pDNA, and mRNA development and manufacturing at AGC Biologics Heidelberg, visit www.agcbio.com/facilities/heidelberg. For more information on our Protein Biologics, pDNA, Cell Therapy, Viral Vector and mRNA drug product services go to www.agcbio.com. About VAR2 Pharmaceuticals ApS VAR2 Pharmaceuticals is a near-clinical stage biotechnology company developing first-in-class therapeutics for onco-fetal Chondroitin Sulfate, a pan-cancer, tumor-specific glycosaminoglycan discovered by VAR2 Pharmaceuticals during malaria research. Founded in 2012, VAR2 Pharmaceuticals is based in Copenhagen and has raised >€20M to date. Our experienced team of innovators and scientists are committed to developing safe and effective cancer therapies targeting this unique cancer-specific carbohydrate modification, with a particular focus on hard-to-treat, recurrent and metastatic cancers. For additional information, please visit www.var2pharma.com. About AGC Biologics: AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan. We currently employ more than 2,500 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is a part of AGC Inc.’s Life Science Company. The Life Science company runs more than 10 global facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit www.agcbio.com. Contact Details Nick McDonald +1 425-419-3555 nmcdonald@agcbio.com Company Website https://www.agcbio.com/

April 24, 2024 12:04 AM Mountain Daylight Time

PharmAla Biotech Advances Global MDMA Production and Research

PharmAla Biotech Holdings Inc

PharmAla Biotech Nick Kadysh joined Steve Darling from Proactive to share exciting developments, announcing significant milestones achieved by the company's joint venture, Cortexa Pty., in Australia. Cortexa has commenced batch manufacturing of GMP LaNeo MDMA 40mg capsules, marking an Australian first. These capsules will support both clinical trials and clinical use under the TGA's Authorised Prescriber pathway. PharmAla's mission is twofold: to address the global shortage of clinical-grade MDMA for clinical trials and commercial sales in selected jurisdictions, and to develop novel drugs in the same class. As the sole provider of clinical-grade MDMA for patient treatments outside of clinical trials, PharmAla is uniquely positioned in the market. According to Kadysh, Cortexa's achievement of domestic Australian manufacturing represents a significant milestone in the local psychedelic landscape. This move strengthens Cortexa's leadership position by establishing a reliable local supply, eliminating the costly and time-consuming burden of importation, and providing seamless access to medication for clinicians and researchers. In addition to this achievement, PharmAla has successfully closed a previously announced non-brokered private placement, raising gross proceeds of $750,000. The company plans to allocate the net proceeds towards securing global patent rights for its portfolio of novel intellectual property assets, manufacturing products for sale, and funding clinical trials for its patented drug candidates. Contact Details Proactive North America Proactive North America +1 604-688-8158 na-editorial@proactiveinvestors.com

April 23, 2024 07:01 PM Eastern Daylight Time

Video

Cloud DX seeing customer loyalty with 2 Ontario Community Paramedic Service contract renewals

Cloud DX

Cloud DX CEO Robert Kaul joined Steve Darling from Proactive to share exciting updates with Proactive regarding the renewal of Master Deployment Agreements with paramedic services in Ontario. These agreements, spanning 12 months with an Ontario County Paramedic Service and 24 months with the Guelph Wellington - City of Guelph Paramedic Service, signify the continued partnership between Cloud DX and these healthcare providers. In Ontario, Community Paramedic Services leverage Cloud DX's Connected Health Remote Patient Monitoring (RPM) services to offer daily monitoring of vital signs, physical symptoms, and chronic conditions to seniors. Through the Cloud DX mobile app, patients can interact with paramedics, facilitating close oversight and empowering patients to manage their own care effectively. Of particular note is the Community Paramedicine for Long-Term Care (CPLTC) program, fully funded by the Ontario provincial government to provide additional care for seniors before admission into long-term care facilities. The recent announcement of an additional $174 million CAD in funding to expand the CPLTC program from 2024 onwards underscores the importance and growth potential of this initiative. Kaul emphasized that contract renewals are a significant sales metric for Cloud DX, demonstrating the company's ability to continue serving satisfied clients effectively. Cloud DX has successfully renewed and extended Master Service Agreements with Community Paramedic Services in 10 Ontario counties, further solidifying its position as a trusted partner in the healthcare industry. Contact Details Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

April 23, 2024 01:43 PM Eastern Daylight Time

Video

Lisata Therapeutics advances lead asset LSTA1 for treatment of advanced solid tumors

Lisata Therapeutics Inc

Lisata Therapeutics CEO David J. Mazzo discusses the oncology company's focus and recent advancements in an interview with Proactive's Stephen Gunnion. Lisata Therapeutics, established 18 months ago through the acquisition of Cend Therapeutics by Caladrius Biosciences, is dedicated to developing technologies aimed at treating solid tumour cancers. The company's primary product, certepetide (LSTA1) is a nine amino acid cyclic peptide designed to target and penetrate tumours. It is used in combination with chemotherapy and other cancer treatments. Currently, the most advanced programme targets metastatic pancreatic ductal adenocarcinoma, with phase 2B results expected later this year. Lisata has also received several orphan drug designations, including for pancreatic cancer, glioblastoma, and osteosarcoma. Additionally, it has a rare paediatric disease designation for osteosarcoma in the US. Mazzo highlighted discussions with regulatory authorities in Australia, the EMA, and the FDA about potential accelerated approval based on upcoming trial results. He expressed optimism about commercializing List-1 as early as 2026 under ideal conditions. Investors can look forward to various clinical and data milestones in the next 12 to 18 months, including potential business development activities. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

April 23, 2024 10:48 AM Eastern Daylight Time

Video

Made in the USA: Ultrahuman plants flag in US with manufacturing facility UltraFactory to make first wearable rings in the country

Ultrahuman

With smart ring market leadership within its sights, Ultrahuman has today announced plans to open a manufacturing facility poised to accelerate its production capacity. The UltraFactory will be located in Indiana. It opens within the next six months and will be the launchpad for Ultrahuman’s next phase of growth. The UltraFactory will offer an end-to-end production capability and is based on the company’s first operational model of such a facility in India. This development comes hot on the heels of a $35 million fresh investment in the company (series B funding round) and reaffirms Ultrahuman’s ambition to become the market leader in the smart ring space in the next 12 to 15 months. The company has already seen phenomenal growth over the past year, becoming the second-largest player in the smart ring market while maintaining profitability. The opening of the new UltraFactory, will add a production capacity of 200,000 smart rings and present an additional $100m revenue opportunity annually. This is a push towards establishing smart ring market leadership in the US. Ultrahuman’s ability to make significant long-term manufacturing investments, supported by its profitability, is unique in the smart rings market. As a result, UltraFactory’s cutting-edge end-to-end production capabilities will enable the company to fully capitalize on what the company sees as its biggest competitive advantage: fast product development and iteration, and speed of execution in rolling out to global markets. With the US market growing in importance for Ultrahuman in recent months, the move will help the company lower costs in shipping and logistics, while aiding the US government in its push to strengthen domestic manufacturing rather than manufacturing in offshore locations, like China. This brings an expected hiring boom of 150 new Ultrahuman employees in the US over the next 12 months split between engineering and research (30%) and commercial operations (70%). Mohit Kumar, Founder and CEO of Ultrahuman commented: “US is an interesting market for us given it has always been huge in terms of demand for the product but we’re also seeing tremendous value from a manufacturing and research perspective. UltraFactory US would enable manufacturing for health tracking smart ring devices and give us the ability to do necessary research to evolve the form factor further.” Ultrahuman has seen phenomenal growth over the past 12 months, becoming the second-largest player in the smart ring market while maintaining profitability. "Our vision of being the top player in terms of both active devices and geographic presence is within reach, thanks to our rapid expansion and the love we've received from our users," added Mohit Kumar. UltraFactory will help Ultrahuman support its recent retail expansion into over 150 outlets worldwide, spanning iconic locations like London’s Selfridges on Oxford Street, Changi Airport in Singapore, and the Virgin megastore in Dubai. In addition to their smart ring called Ring AIR, the Ultrahuman product suite includes a continuous glucose monitoring wearable called M1 Live, a home health device called Ultrahuman Home and a preventive blood testing product called Blood Vision. Their platform integrates glucose, sleep, movement, blood markers, and HRV, offering a comprehensive approach to health monitoring. "Our growth is a testament to the user love for our products, highlighted by industry-leading NPS and engagement metrics since the launch of our latest model, the Ring AIR. Our relentless focus on improving user experience through continuous firmware and software updates is what sets us apart," Mohit Kumar emphasized. "Shipping a new firmware version every 2 weeks and weekly app improvements reflect our commitment to excellence and our speed of execution, our biggest competitive advantage. We’ve also iterated on hardware at the speed of software by designing novel devices like Ultrahuman Home, a home health monitor.” Looking ahead, Ultrahuman is on track to surpass $100 million in annualized revenue run rate (ARR) by the end of 2024, a milestone that will be achieved profitably. "Our ability to make long-term manufacturing investments, supported by our profitability, is unique in the smart ring market," Mohit Kumar noted. Ultrahuman's dedication to scientific validation and innovation is further evidenced by the completion of a clinical trial involving 105 participants, aimed at validating the ‘Metabolic Score’ generated on the Ultrahuman platform. "Our long-term investment in R&D and intellectual property is a cornerstone of our strategy, ensuring that our products not only meet but exceed the highest standards of efficacy and reliability," Mohit Kumar concluded. About Ultrahuman Ultrahuman is the world's most advanced metabolic fitness platform. Ultrahuman’s products include the Ultrahuman M1(continuous glucose monitoring sensor), the Ultrahuman Ring and Blood Vision, a preventive blood testing platform with the pioneering UltraTrace™ technology. By collating different biomarkers, Ultrahuman is helping people improve their energy levels and lifestyle, track their workout, sleep and recovery, and avoid metabolic disorders. For more information and updates on Ultrahuman, please visit ultrahuman.com or follow us on Facebook, Instagram, Twitter, LinkedIn, and YouTube. Contact Details Ultrahuman Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Ultrahuman Hisham Syed hisham@ultrahuman.com Company Website https://www.ultrahuman.com/

April 23, 2024 10:15 AM Eastern Daylight Time

Image

ANGLE achieves breakthrough with EU patent for CellKeep technology, with the US to follow

ANGLE PLC

ANGLE PLC chief executive Andrew Newland discussed significant advancements in the company's technology, including a European patent for the CellKeep slide, with US intellectual property protection from the US set to follow soon. Newland told Proactive's Stephen Gunnion that CellKeep significantly improves the deposition of cancer cells on microscope slides, a common issue in medical laboratories. This method notably reduces cell loss during the transfer process by over 70%, addressing a longstanding problem in the industry. The innovation involves a special funnel attached to the slide, allowing gentle centrifugation and liquid removal while maintaining cell integrity, thereby increasing the effectiveness of subsequent analyses. Additionally, Newland highlighted the development of optimized antibodies for cell phenotyping, which are integrated into ANGLE's Parsortix system. This integration is packaged as the Portrait Plus CTC Staining Kit, simplifying the process for less experienced labs and extending market reach. The kit includes a mix of dehydrated antibodies, designed for ease of use and long shelf life, enhancing the diagnostic process's reliability and efficiency. Commercially, ANGLE has introduced these innovations in a comprehensive kit format, priced at £3,000 for ten samples, significantly enhancing the company’s value offering. Newland also touched on ANGLE’s positive business trajectory, mentioning a breakthrough in DNA profiling and a substantial contract with a major pharmaceutical company, which could potentially yield significant revenues through the development of companion diagnostics. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

April 23, 2024 09:17 AM Eastern Daylight Time

Video

World-Renowned Neurologist and Bestselling Author Joins Forum Health’s Annual Integrative Medicine Summit

Forum Health

Forum Health, LLC, leading nationwide network of integrative and functional medicine providers, is thrilled to announce Dr. Dale Bredesen, a trailblazing neuroscientist and pioneer in Alzheimer's disease research, as the keynote speaker at the Forum Health Summit: Emerging Therapies in Integrative Medicine. Register for the Forum Health Summit here. With a career spanning over four decades, Dr. Bredesen has made groundbreaking contributions to neurological research, cognitive decline treatment, and Alzheimer's disease with his renowned Bredesen Protocol - the only Alzheimer’s treatment where the most patients have stabilized or improved. Dale Bredesen, MD: “I’m honored to be the keynote speaker at Forum Health’s annual summit. They are setting the stage to discuss the latest advancements in integrative medicine, bringing together the nation’s top providers, and providing me with the opportunity to share insights and collaborate with my colleagues to drive innovation and progress." Dr. Bredesen's presentation will delve into the latest advancements in Alzheimer's research and shed light on the importance of personalized medicine in combating cognitive decline. Attendees will receive invaluable insights into treatment modalities and preventative measures to preserve brain health. Phil Hagerman, Forum Health CEO: "We’re thrilled to have Dr. Bredesen join us this year. His unparalleled expertise and contributions to the medical community have been instrumental in advancing new treatment approaches to transform the landscape of Alzheimer's disease." The Forum Health Summit is a one-day conference that brings together the top thought leaders in integrative and functional medicine. Attendees receive the latest on emerging research, cutting-edge diagnosis, and treatment protocols for complex clinical cases from expert leaders in the field. The event will also feature presentations from industry experts including: Sahar Swidan, Pharm.D., BCPS, ABAAHP, FAARFM, FACA - President and CEO of NeuroPharm, and internationally renowned speaker on pain management and HRT Paul Anderson, MD - Recognized educator and clinician in integrative and naturopathic medicine focused on complex infecious, chronic and oncologic illnesses Thomas G. Gulliams, Ph.D. - Former VP of Ortho Molecular and expert in the therapeutic uses of dietary supplements Registration for this event is exclusive to licensed medical professionals, space limited and this event is expected to sell out. Register here. About Forum Health Forum Health, LLC is a nationwide provider of personalized healthcare steeped in the powerful principles of functional and integrative medicine. Our providers take a root-cause approach to care exploring lifestyle, environment, and genetics to help each patient achieve their ultimate health goals. Members have access to advanced medical treatments and technology, with care plans informed by data analytics and collaborative relationships. For more, visit www.forumhealth.com. Contact Details Forum Health Britt Wittelsberger +1 410-852-0738 bwittelsberger@forumhealth.com Company Website https://forumhealth.com

April 23, 2024 08:50 AM Eastern Daylight Time

Image

1 ... 38 39 40 41 42 ... 308